Monte Rosa Therapeutics Stock Discussion

$Monte Rosa Therapeutics (GLUE.US)$ Novartis has agreed to pay Monte Rosa $150 million up front. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, as well as tiered royalties on ex-U.S. net sales. Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT...

$Monte Rosa Therapeutics (GLUE.US)$ Monte Rosa Therapeutics Announced It Will Present Preclinical Data On The Potential Of Its Highly Selective Cyclin-dependent Kinase 2 (Cdk2)-directed Molecular Glue Degrader To Treat Hr-positive/Her2-negative Breast Cancer At The 2024 San Antonio Breast Cancer Symposium

$Monte Rosa Therapeutics (GLUE.US)$ Reuters· 9 mins ago
Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis to Advance T and B Cell-Modulating Vav1-Directed Molecular Glue Degraders

$Monte Rosa Therapeutics (GLUE.US)$
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics (Nasdaq: GLUE) has closed its global exclusive development and commercialization license agreement with Novartis for VAV1-directed molecular glue degraders (MGDs), including MRT-6160. The deal includes a $150 million upfront paymentand potential earnings of up to $2.1 bill...

$Monte Rosa Therapeutics (GLUE.US)$
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Monte Rosa Therapeutics (Nasdaq: GLUE) presented preclinical data on their CDK2-directed molecular glue degrader (MGD), MRT-9643, for treating HR-positive/HER2-negative breast cancer. The data shows that MRT-9643 demonstrates superior selectivity comp...

$Monte Rosa Therapeutics (GLUE.US)$
🔥👹👊 GHOST (STOCK, ETF, BITCOIN...) = BLOCK SHORT = CHIF LAO = THE MORE YOU BUY THE MORE YOU LOSS, TRADE ONE WAY TO HELL, ARE YOU SMART ? 🤔
HOW DO YOU WANT TO PUNISH CHEATERS ? 👽

$Monte Rosa Therapeutics (GLUE.US)$
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Monte Rosa Therapeutics has provided an update on its Phase 1/2 study of MRT-2359 in patients with MYC-driven solid tumors. The study demonstrated a favorable safety profile and achieved targeted GSPT1 degradation levels using a 21 days on, 7 days off drug dosing schedule in heavily pretreated patients.
The recommended P...

$Monte Rosa Therapeutics (GLUE.US)$ Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
3 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients
Recommended Phase 2 dose determine...

$Monte Rosa Therapeutics (GLUE.US)$ thats pretty good revenue. But dont buy here. wait for it to calm down.

$Monte Rosa Therapeutics (GLUE.US)$
Monte Rosa Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Versant Venture Capital VI, L.P.(6.6%),Versant Ventures VI GP, L.P.(6.6%), etc.